Teresa Bonfill

Teresa Bonfill

Auto-generated profile, based on publicly available information

Teresa Bonfill

Hospital Universitari Parc Taulí, Department of Medical Oncology, Sabadell, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2017 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
MPM. Pastor
M. Pastor
ALAntonio López-Pousa
Antonio López-Pousa
EBEDEL DEL BARCO-MORILLO
EDEL DEL BARCO-MORILLO
PSPEDRO PÉREZ SEGURA
PEDRO PÉREZ SEGURA
BAB. Gonzalez Astorga
B. Gonzalez Astorga
RMRicard Mesia
Ricard Mesia
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiation therapy is an essential component of curative-intent of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.

18 February 2009 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
CPCarles Pericay
Carles Pericay
ALAnna López
Anna López
JSJoan Ramón Soler
Joan Ramón Soler
TBTeresa Bonfill
Teresa Bonfill
EDEmma Dotor
Emma Dotor
ESEugeni Saigí
Eugeni Saigí

20 November 2017 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
MBMarta Bonet
Marta Bonet
TBT. Bonfill
T. Bonfill
MFMiriam Nuñez Fernandez
Miriam Nuñez Fernandez
LVL. De Verdonces
L. De Verdonces
EME. Mur
E. Mur
Meritxell ArenasMeritxell Arenas
Meritxell Arenas

19 May 2010 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
IMIrene Moya-Horno
Irene Moya-Horno
RNRosa Querol Niñerola
Rosa Querol Niñerola
TATeresa Bonfill Abella
Teresa Bonfill Abella
EPElsa Dalmau Pórtulas
Elsa Dalmau Pórtulas
EGEnrique Gallardo-Díaz
Enrique Gallardo-Díaz
CPCarles Pericay
Carles Pericay

20 August 2014 in The Oncologist
Verified
Journal Article
Open access
PDF file
JBJoaquim Bellmunt
Joaquim Bellmunt
CSCristina Suarez
Cristina Suarez
EGEnrique Gallardo
Enrique Gallardo
JRJordi Rodon
Jordi Rodon
FPFrancesc Pons
Francesc Pons
JCJoan Carles
Joan Carles
The combination of gemcitabine plus capecitabine and sunitinib (GCS) shows activity in metastatic renal cell carcinoma (mRCC). We tested the multitargeted “chemo-switch” regimen as first-line treatment in patients with mRCC. We assessed the maximum tolerated dose and antitumor activity of GCS in treatment-naïve, advanced mRCC patients. Treatment consisted of intravenous gemcitabine on days 1 and 8, oral capecitabine twice daily on days 1–14, and oral sunitinib daily for six 21-day cycles, followed by sunitinib monotherapy at the investigator's discretion. Dose level 0 (DL0) was gemcitabine 1,000 mg/m2 per day plus capecitabine 650 mg/m2 per 12 hours plus sunitinib 37.5 mg/day; DL1 was gemcitabine 1,000 mg/m2 per day plus capecitabine 850 mg/m2 per 12 hours plus sunitinib 37.5 mg/day. Sixteen patients were enrolled. At DL1, two of four patients had dose-limiting toxicity (DLT; grade 3 diarrhea and grade 4 thrombocytopenia). The dose was reduced to DL0 when only 1 of 12 patients experienced DLT (grade 3 diarrhea, grade 3 mucositis, and grade 3 thrombocytopenia). Dose reductions were frequent (58% of patients), and only seven patients were able to receive the three drugs for more than three cycles. One patient achieved a complete response, three had partial responses, and the best response for four was stable disease. The safety profile of the combination does not seem manageable in this patient population. No further development of the combination is recommended.

1 April 2009 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
TBTeresa Bonfill
Teresa Bonfill
EDEmma Dotor
Emma Dotor
ADAnna Darnell
Anna Darnell
ÀCÀlex Casalots
Àlex Casalots
JBJordi Bombardó
Jordi Bombardó
CPCarles Pericay
Carles Pericay